DaVita Inc. $DVA Stock Position Trimmed by Mount Lucas Management LP

Mount Lucas Management LP trimmed its position in shares of DaVita Inc. (NYSE:DVA) by 65.6% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 3,131 shares of the company’s stock after selling 5,961 shares during the period. Mount Lucas Management LP’s holdings in DaVita were worth $446,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in DVA. Envestnet Asset Management Inc. boosted its position in shares of DaVita by 7.9% during the first quarter. Envestnet Asset Management Inc. now owns 55,255 shares of the company’s stock worth $8,452,000 after buying an additional 4,048 shares during the period. Victory Capital Management Inc. boosted its position in DaVita by 31.9% during the 1st quarter. Victory Capital Management Inc. now owns 57,074 shares of the company’s stock worth $8,731,000 after acquiring an additional 13,802 shares during the period. VCI Wealth Management LLC acquired a new position in DaVita during the 1st quarter worth $650,000. Avantax Advisory Services Inc. bought a new position in DaVita in the 1st quarter valued at about $227,000. Finally, Cetera Investment Advisers lifted its stake in shares of DaVita by 56.9% in the 1st quarter. Cetera Investment Advisers now owns 7,658 shares of the company’s stock worth $1,171,000 after acquiring an additional 2,778 shares during the period. Institutional investors and hedge funds own 90.12% of the company’s stock.

DaVita Stock Down 3.4%

NYSE:DVA opened at $117.41 on Tuesday. The stock has a fifty day simple moving average of $127.34 and a 200 day simple moving average of $135.16. The firm has a market capitalization of $8.29 billion, a price-to-earnings ratio of 12.09, a price-to-earnings-growth ratio of 0.91 and a beta of 1.13. DaVita Inc. has a 1-year low of $115.39 and a 1-year high of $179.60.

DaVita (NYSE:DVA) last posted its quarterly earnings data on Wednesday, October 29th. The company reported $2.51 EPS for the quarter, missing analysts’ consensus estimates of $3.17 by ($0.66). The firm had revenue of $3.42 billion for the quarter, compared to analysts’ expectations of $3.43 billion. DaVita had a net margin of 5.80% and a return on equity of 815.62%. DaVita’s quarterly revenue was up 4.8% compared to the same quarter last year. During the same period in the prior year, the company posted $2.59 earnings per share. DaVita has set its FY 2025 guidance at 10.350-11.150 EPS. Equities analysts predict that DaVita Inc. will post 10.76 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms recently commented on DVA. Weiss Ratings reiterated a “hold (c)” rating on shares of DaVita in a research note on Thursday. Barclays decreased their price target on DaVita from $149.00 to $143.00 and set an “equal weight” rating for the company in a research note on Thursday, October 30th. Truist Financial set a $140.00 price objective on DaVita in a research note on Tuesday, October 14th. Cowen reaffirmed a “hold” rating on shares of DaVita in a research note on Monday, November 3rd. Finally, TD Cowen dropped their target price on shares of DaVita from $154.00 to $133.00 and set a “hold” rating on the stock in a report on Monday, November 3rd. Five analysts have rated the stock with a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, DaVita presently has an average rating of “Reduce” and a consensus price target of $148.00.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.